Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Unresectable HER2-Negative Breast Carcinoma”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445908
What this trial is testing

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer and HR+/HER2- BC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 175
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing

Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50
Early research (Phase 1)Ended earlyNCT04060862
What this trial is testing

Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 20
Testing effectiveness (Phase 2)Looking for participantsNCT06179303
What this trial is testing

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable HER2-Negative Breast Carcinoma+3 more
University of Washington 60
Testing effectiveness (Phase 2)Looking for participantsNCT05564377
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+12 more
National Cancer Institute (NCI) 2,900
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Early research (Phase 1)Study completedNCT02776917
What this trial is testing

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Who this might be right for
Breast Neoplasms
Barbara Parker, MD 23
Large-scale testing (Phase 3)Study completedNCT04732598
What this trial is testing

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Japanese Foundation for Cancer Research 281
Testing effectiveness (Phase 2)Study completedNCT05340413
What this trial is testing

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
SOLTI Breast Cancer Research Group 65
Testing effectiveness (Phase 2)Study completedNCT00951054
What this trial is testing

NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 61
Testing effectiveness (Phase 2)Looking for participantsNCT06042894
What this trial is testing

SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 58
Large-scale testing (Phase 3)Looking for participantsNCT07071337
What this trial is testing

SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Not applicableNot Yet RecruitingNCT06993506
What this trial is testing

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
HER2-negative Breast CancerRecurrenceMetastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 500
Large-scale testing (Phase 3)Study completedNCT01935492
What this trial is testing

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer
Borstkanker Onderzoek Groep 420
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06308939
What this trial is testing

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 81
Large-scale testing (Phase 3)Looking for participantsNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 895
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383196
What this trial is testing

Onvansertib + Paclitaxel In TNBC

Who this might be right for
Breast CancerInvasive Breast CancerUnresectable Breast Carcinoma+7 more
Antonio Giordano, MD 50
Load More Results